Infectious Disease and Vaccines Pipeline Reports

berries

DelveInsight is helping worldwide Pharmaceutical companies with its Market Intelligence Reports.

VISIT OUR WEBSITE

Infectious Diseases and Vaccines

The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the development of a first vaccine, and even routine vaccinations, such as those for influenza can be improved in terms of safety and efficacy. Such unmet needs are driving the continued development of ID vaccines.

Get  Notified About Whats in Others Pipeline

The research work for curing Infectious disease has rapidly assumed a prioritized role within the overall scientific portfolio. The number of vaccines development underway has increased substantially for the HCV, HIV, Tuberculosis and Influenza infections.

Get notified about all the under development vaccines worldwide and the technology they are using, stage of development, their targets, mechanism of action with our Pipeline reports. The best strategic report that will not even give you the overall developing drug profiles but also therapeutic assessment and comparative analysis at every step such as monotherapy, combination, route of administration.

Pipeline Insights Reports

HCV Vaccine-Pipeline Insights, 2014 

HIV Vaccine-Pipeline Insights, 2014 

Influenza Vaccine-Pipeline Insights, 2014 

Tuberculosis Vaccine-Pipeline Insights, 2014

ASK FOR SAMPLE PAGES NOW

For further information email us at info@delveinsight.com

Ebola Virus Drugs Approved or Still in Pipeline. What’s the mystery?

Get informed about the Current Drugs in Pipeline with DelveInsight “’Ebola Viral InfectionsPipeline Insights, 2014′, Report

About Virus

Ebola virus disease (formerly known as Ebola haemorrhagic fever) is a severe, often fatal illness, with a case fatality rate of up to 90%. Ebola first appeared in 1976 in 2 simultaneous outbreaks, in Nzara, Sudan, and in Yambuku, Democratic Republic of Congo. The latter was in a village situated near the Ebola River, from which the disease takes its name.

The 2014 Ebola outbreak is one of the largest Ebola outbreaks in history and the first in West Africa. It is affecting four countries in West Africa: Guinea, Liberia, Nigeria, and Sierra Leone.

Disease update

Confirmed, probable, and suspect cases and deaths from Ebola virus disease in Guinea, Liberia, Nigeria, and Sierra Leone, as of 16 August 2014

Total Cases in West Africa

sdfsa

Cases and Death by Country

dsaasd

 

Vaccine and treatment

No licensed vaccine for EVD is available. Several vaccines are being tested, but none are available for clinical use.

Fast Track Drugs in Pipeline

Tekmira

In March 5, 2014, U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of TKM-Ebola, an anti-Ebola viral therapeutic of Tekmira Pharmaceuticals Corporation.

The TKM-Ebola drug is being developed by Tekmira and the U.S. Department of Defense’s medical countermeasure systems biodefense therapeutics joint product management office under a $140 million contract.

The anti-Ebola virus RNAi therapeutic has been used in preclinical studies to treat previously infected “non-human primates”, with results showing 100 percent protection from an otherwise lethal dose of Zaire Ebola virus.

In January 2014, Tekmira commenced a Phase I clinical trial using TKM-Ebola. The TKM-Ebola Phase I clinical trial is a randomized, single-blind, placebo-controlled study involving single ascending doses and multiple ascending doses of TKM-Ebola. The study will assess the safety, tolerability and pharmacokinetics of administering TKM-Ebola to healthy adult subjects.

RISK

KM-Ebola may not prove to be an effective anti-viral therapy for hemorrhagic fever viruses; data from the TKM-Ebola Phase I human clinical trial may not be available as currently anticipated, or at all; the U.S. Department of Defense may suspend or terminate its participation in the TKM-Ebola program; the Fast Track designation from the FDA may not result in faster development times or earlier approvals; and Tekmira’s products may not prove to be effective or as potent as currently believed.

AVI-7537

On Sep 18, 2012, U.S. Food and Drug Administration (FDA) has granted Fast Track status for the development of Sarepta Therapeutic’s lead infectious disease drug candidate, AVI-7537, a different type modified RNA molecule. AVI-7537 is directed against one of the three Ebolavirus genes (VP24). The chemistry platform utilized for development is PMOplus. AVI-7537 also works via a different mechanism to block the viral protein from being made.

Sarepta had been conducting Phase 1 safety trials with the drug alone and together another Ebola-directed PMOplus molecule (AVI-7539, with the combination called AVI-6002).

Currently Given Non-Licensed Drug

ZMapp

American missionary Ebola patients, Dr. Kent Brantly and Nancy Writebol are given biotech product, called ZMapp, are indeed still experimental – it’s not yet approved for human use, and not yet even in phase I clinical trials.

The ZMapp three-antibody cocktail isn’t a vaccine. Instead, it provides an artifical immune response against sugar-tagged proteins on the outside of the Ebolavirus.

ZMappTM is composed of three “humanized” monoclonal antibodies manufactured in, specifically Nicotiana. It is an optimized cocktail combining the best components of MB-003 (Mapp) and ZMAb (Defyrus/PHAC). ZMappTM was first identified as a drug candidate in January 2014 and has not yet been evaluated for safety in humans.

WHAT’S IN THE PIPELINE?

There are about a half dozen Ebola drugs and vaccines in development, several of which have received funding from the U.S. 

For more information on Pipeline drugs of Ebola Virus get the DelveInsight’s Report Ebola Viral Infections-Pipeline Insights, 2014′ in just $1250.

For more information contact info@delveinsight.com

Or

Please visit Report BuyerReportLinkerASD MediaMarket Report (Japan)Market Publishers VPG MarketResearch Bharat Book Bureau

Sources:

http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/SpeedingAccesstoImportantNewTherapies/ucm128291.htm

http://www.tekmira.com/pipeline/tkm-ebola.php

http://www.cdc.gov/vhf/ebola/outbreaks/guinea/

http://freedomoutpost.com/2014/08/west-africans-streaming-across-u-s-southern-border-carrying-ebola-virus/

http://www.who.int/csr/don/2014_08_19_ebola/en/

http://www.mappbio.com/zmapinfo.pdf

https://www.bharatbook.com/healthcare-market-research-reports-511074/ebola-viral-infections-pipeline-insights1.html

http://www.latimes.com/science/sciencenow/la-sci-sn-ebola-serum-20140804-story.html

Metastatic Prostate Cancer-Pipeline Insights, 2014

DelveInsight’s,“ Metastatic Prostate Cancer-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Metastatic Prostate Cancer. This report provides information on the therapeutic development based on the Metastatic Prostate Cancer dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Scope
– The report provides a snapshot of the global therapeutic landscape of Metastatic Prostate Cancer
– The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
– Coverage of the Metastatic Prostate Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
– The report reviews key players involved in the therapeutics development for Metastatic Prostate Cancer and also provide company profiling
– The report also gives the information of dormant and discontinued pipeline projects
– Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
– Complete Pipeline intelligence and complete understanding over therapeutics development for Metastatic Prostate Cancer
– Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
– Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics
– Developing strategic initiatives to support your drug development activities.
– Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
– Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
– Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table of Contents
– Metastatic Prostate Cancer Overview
– Metastatic Prostate Cancer Pipeline Therapeutics
– Metastatic Prostate Cancer Therapeutics under Development by Companies
– Metastatic Prostate Cancer Late Stage Products (Filed and Phase III)
– Comparative Analysis
– Metastatic Prostate Cancer Mid Clinical Stage Products (Phase II)
– Comparative Analysis
– Metastatic Prostate Cancer Early Clinical Stage Products (Phase I and IND Filed)
– Comparative Analysis
– Metastatic Prostate Cancer Discovery and Pre-Clinical Stage Products
– Comparative Analysis
– Drug Candidate Profiles
– Metastatic Prostate Cancer – Therapeutics Assessment
– Assessment by Monotherapy Products
– Assessment by Combination Products
– Assessment by Route of Administration
– Assessment by Molecule Type
– Metastatic Prostate Cancer – Discontinued Products
– Metastatic Prostate Cancer – Dormant Products
– Companies Involved in Therapeutics Development for Metastatic Prostate Cancer
– Appendix
– Methodology
– Contact Us
– Disclaimer

List of Tables

– Number of Products under Development for Metastatic Prostate Cancer, 2014
– Number of Products under Development by Companies
– Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
– Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
– Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
– Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
– Drug Candidates Profiles
– Metastatic Prostate Cancer Assessment by Monotherapy Products
– Metastatic Prostate Cancer Assessment by Combination Products
– Metastatic Prostate Cancer Assessment by Route of Administration
– Metastatic Prostate Cancer Assessment by Stage and Route of Administration
– Metastatic Prostate Cancer Assessment by Molecule Type
– Metastatic Prostate Cancer Assessment by Stage and Molecule Type
– Metastatic Prostate Cancer Therapeutics – Discontinued Products
– Metastatic Prostate Cancer Therapeutics – Dormant Products
– Products under Development by Companies, 2014

List of Figures

– Number of Products under Development for Metastatic Prostate Cancer, 2014
– Late Clinical Stage Products (Filed and Phase III), 2014
– Mid Clinical Stage Products (Phase II), 2014
– Early Clinical Stage Products (Phase I and IND Filed), 2014
– Discovery and Pre-Clinical Stage Products, 2014
– Metastatic Prostate Cancer Assessment by Monotherapy Products
– Metastatic Prostate Cancer Assessment by Combination Products
– Metastatic Prostate Cancer Assessment by Route of Administration
– Metastatic Prostate Cancer Assessment by Stage and Route of Administration
– Metastatic Prostate Cancer Assessment by Molecule Type
– Metastatic Prostate Cancer Assessment by Stage and Molecule Type

Report Pricing
Single User License: $1250
Site License:$2500
Global License:$4000

For Sample Pages and Report, please contact us at info@delveinsight.com

Brain Hemorrhage-Pipeline Insights, 2014

DelveInsight’s, Brain Hemorrhage-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Brain Hemorrhage. This report provides information on the therapeutic development based on the Brain Hemorrhage dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Scope
– The report provides a snapshot of the global therapeutic landscape of Brain Hemorrhage
– The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
– Coverage of the Brain Hemorrhage pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
– The report reviews key players involved in the therapeutics development for Brain Hemorrhage and also provide company profiling
– The report also gives the information of dormant and discontinued pipeline projects
– Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
– Complete Pipeline intelligence and complete understanding over therapeutics development for Brain Hemorrhage
– Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
– Devise corrective measures for pipeline projects by understanding Brain Hemorrhage pipeline depth and focus of Indication therapeutics
– Developing strategic initiatives to support your drug development activities.
– Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
– Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
– Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table of Contents

– Brain Hemorrhage Overview
– Brain Hemorrhage Pipeline Therapeutics
– Brain Hemorrhage Therapeutics under Development by Companies
– Brain Hemorrhage Late Stage Products (Filed and Phase III)
– Comparative Analysis
– Brain Hemorrhage Mid Clinical Stage Products (Phase II)
– Comparative Analysis
– Brain Hemorrhage Early Clinical Stage Products (Phase I and IND Filed)
– Comparative Analysis
– Brain Hemorrhage Discovery and Pre-Clinical Stage Products
– Comparative Analysis
– Drug Candidate Profiles
– Brain Hemorrhage – Therapeutics Assessment
– Assessment by Monotherapy Products
– Assessment by Combination Products
– Assessment by Route of Administration
– Assessment by Molecule Type
– Brain Hemorrhage – Discontinued Products
– Brain Hemorrhage – Dormant Products
– Companies Involved in Therapeutics Development for Brain Hemorrhage
– Appendix
– Methodology
– Contact Us
– Disclaimer

List of Tables

– Number of Products under Development for Brain Hemorrhage, 2014
– Number of Products under Development by Companies
– Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
– Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
– Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
– Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
– Drug Candidates Profiles
– Brain Hemorrhage Assessment by Monotherapy Products
– Brain Hemorrhage Assessment by Combination Products
– Brain Hemorrhage Assessment by Route of Administration
– Brain Hemorrhage Assessment by Stage and Route of Administration
– Brain Hemorrhage Assessment by Molecule Type
– Brain Hemorrhage Assessment by Stage and Molecule Type
– Brain Hemorrhage Therapeutics – Discontinued Products
– Brain Hemorrhage Therapeutics – Dormant Products
– Products under Development by Companies, 2014

List of Figures

– Number of Products under Development for Brain Hemorrhage, 2014
– Late Clinical Stage Products (Filed and Phase III), 2014
– Mid Clinical Stage Products (Phase II), 2014
– Early Clinical Stage Products (Phase I and IND Filed), 2014
– Discovery and Pre-Clinical Stage Products, 2014
– Brain Hemorrhage Assessment by Monotherapy Products
– Brain Hemorrhage Assessment by Combination Products
– Brain Hemorrhage Assessment by Route of Administration
– Brain Hemorrhage Assessment by Stage and Route of Administration
– Brain Hemorrhage Assessment by Molecule Type
– Brain Hemorrhage Assessment by Stage and Molecule Type

Report Pricing

Single User: USD 1250
Site License: USD 2500
Global License: USD 4000

To order the Sample Pages and the Report please contact below:

Email: info@delveinsight.com

Source: DelveInsight

Rheumatoid Arthritis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

DelveInsight’s, “ Rheumatoid Arthritis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible.

Scope
– A snapshot of the global Market therapeutics scenario for Rheumatoid Arthritis.
– A review of the marketed products under prescription for Rheumatoid Arthritis, regulatory information and marketing status.
– Coverage of global patent coverage and detailed commentaries on the US patent challenges.
– Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
– Product profiles for marketed products for Rheumatoid Arthritis with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
– Coverage of API Manufacturers for Rheumatoid Arthritis drugs in the United States, Europe and Asian Regions with location details.
– Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Rheumatoid Arthritis drugs.
– Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Rheumatoid Arthritis drugs.
– Coverage of Rheumatoid Arthritis Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
– Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
– Key discontinued Marketed products.
– Global Sales Figure from 2011-2015.

Reasons to buy
– Evaluate the marketing status and exclusivity details of Rheumatoid Arthritis key products to exploit opportunities for generic drug development opportunities.
– Identify and understand important and diverse types of therapeutics under Phase III development for Rheumatoid Arthritis.
– Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to ‘Disease’.
– API intelligence over marketed drugs for Rheumatoid Arthritis and gaining primary intelligence over active ingredients manufacturers across the globe.
– API intelligence over leading Phase III pipeline drugs.
– Develop and design strategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
– Understanding the scope of the Phase III Drugs with nil regulatory filings.
– Understanding the chemical route of synthesis of approved drugs for Rheumatoid Arthritis.
– Uncovering opportunities in the rapidly growing the US markets.

Table of Contents

– Indication Overview
– Marketed Drugs Assessment
– Marketed Details of Drugs by Application Type
– Marketed Details of Drugs (NDA) by Marketing Status
– Marketed Details of Drugs by Patent Expiration Timeline
– The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
– The API Manufacturers by the United States Drug Master File (US DMF) Status
– The API Manufacturers by the US DMF Status (Drug Specific)
– The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
– The API Manufacturers by the US DMF Status (Drug Specific)
– Drugs Market Data and Forecasted Sales Figures (2011-2015)
– Marketed Drugs Information
– Drugs Description
– Route of Synthesis
– Global Active Pharmaceutical Manufacturers
– Approval Status
– Patent and Exclusivity Details
– Company Overview
– Phase III Drugs Information
– Phase III Drugs Description
– The United States Drug Master Filings (US DMF)
– Discontinued Drugs Information

List of Tables
Rheumatoid Arthritis Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Rheumatoid Arthritis Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Rheumatoid Arthritis Therapeutic Market, US, (Year), 2014
Rheumatoid Arthritis Marketed Drugs, API Manufacturers by US DMF Status, 2014
Rheumatoid Arthritis Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Rheumatoid Arthritis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Rheumatoid Arthritis Therapeutic Market, Global Sales (in million USD), 2014
Rheumatoid Arthritis Marketed Drugs, API Manufacturers, Global, 2014
Rheumatoid Arthritis Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Rheumatoid Arthritis, 2014

List of Figures
Rheumatoid Arthritis Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Rheumatoid Arthritis Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Rheumatoid Arthritis Therapeutic Market, US, (Year), 2014
Rheumatoid Arthritis Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Rheumatoid Arthritis Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Rheumatoid Arthritis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Rheumatoid Arthritis Therapeutic Market, Global Sales (in million USD), 2014
Rheumatoid Arthritis Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

Report Pricing 
Single User: USD 2000
Site License: USD 4000
Global License: USD 6000

To order the Sample Pages and the Report please contact below

Email: info@delveinsight.com

Source: DelveInsight

Delveinsight Picks Up The Pace With Its Newly Launched Drug Pipeline Reports!!!

Over the past six months, DelveInsight has proven its value to their customers with its excellent deliverables. Now newly launched DelveInsight’s Pipeline Reports is the answer to all looking for top notch drug development information.

In the fast-paced, competitive field of clinical research, organizations must constantly be in tune to industry happenings, the latest business news, new drugs in the pipeline, trends impacting the industry, emerging markets of clinical research, and much more to maintain an edge for continued success. DelveInsight offers a complete array of pipeline information under “Pharm Insights” providing companies with the necessary tools to keep them in the light and in touch with the unpredictable nature of the industry.

DelveInsight Pipeline Reports will provide complete Pipeline intelligence and complete understanding over therapeutics development. These reports helps in developing strategic initiatives to support your drug development activities, optimizing portfolio, developing  and designing in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

These reports are available with many resellers like Report Linkers, Report Buyers, Report Stack, Bharat Book Bureau and Market Reports. Ask for sample reports now!

For more information please contact info@delveinsight.com

Pipeline1

DelveInsight’s Marketed and Pipeline Reports Going Viral!

If a market is growing enormously, you need to understand what’s nourishing it

 

DelveInsight Report

DelveInsight has launched its Reports under two brands Pharm Delve and Pharm Insights.

Pharm Delve reports are known for its extensive detailed information of the Marketed drugs– Global Market, API Market & Manufacturers across the US, Europe and Asia specifically China and India and Phase III Pipeline drugs information. These reports provide whole list of companies interested in your business. It gives you the most up to date information on drug marketed data, patent data, upcoming API with lots of potential in market, interested Generic Drug Companies, Active Pharmaceutical Ingredient (API) Manufacturers to determine which companies and therapies are emerging leaders while understanding the market needs.

Pharm Insights covers the pipeline reports. Mechanism of Action Reports launched has become the most known and on demand amongst the clients. The report has highlighted all the under development drugs falling under the specific MOA with the comparative analysis at various stages and therapeutics assessment by monotherapy and combination products and molecule type drug information. The reports have covered each and every detail of the drugs while chemical information and company profile are considered thoroughly.

Five worth Reason for Spending on these Reports

  1. Track your closest Competitors
  2. Identifying potential customers
  3. Prioritizing new drug intermediates to add to the portfolio
  4. Uncovering opportunities Globally
  5. Organic as well as Inorganic Growth

Who can buy these Reports?

  • Pharma Companies
  • Drug Development Companies
  • Generic Manufacturing Companies
  • API Manufacturers
  • Institutions/Universities

 Where to buy?

You can buy these reports from the resellers given : Report Buyer, Report Linker, ASD Media, VPG Market Research, Market Publishers, Bharat Book Bureau and Report stack

About DelveInsight

DelveInsight is a Business consultant and Knowledge Partner and have extensive experience across the value chain of pharmaceutical industry. We provide cutting-edge market and pipeline analysis and API intelligence to the Pharma and Biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies.

At DelveInsight, we believe what we do matters. We are passionate about our work, inspired by the impact it has on our business and our customers. As a team, we believe in winning as one – collaborating to reach shared goals, and developing through challenging and meaningful experiences. The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavor the dimensions of the fast growing market by providing clear and forthright business recommendations to help clients evaluate potential paths and make vital decisions at all stages of a product’s lifecycle and across multiple business and therapeutic areas.